| Tumour Group / Site |
| Trial Title | Opening Date |
|---|
Breast
|
| A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer
(AstraZeneca Begonia)
| 2019
|
| | A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib NATALEE)
(Novartis CLEE011012301C /TRIO033)
| 2019
|
| | A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-postive unresectable locally advanced or metastatic breast cancer (Syneos Tulip) | 29Jul2019 |
| | A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
(CCTG MA.39)
| 1May2019 |
| | A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2)
(AstraZeneca Violette) | Sept 2018
|
| | A DOUBLE-BLIND, PLACEBO-CONTROLLED,RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST
(Roche CO40016 Ipatunity 130) | 16Apr2018
|
| | Partial breast irradiation using interstitial permanent Pd 103 seed implant
(PBSI-Radiation) | May
2012 |
CNS
| |
| |
GI
|
| |
|
GU-Bladder
| | An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
(Astellas 7465 0301)
| 2019
|
| | A Phase 3 Study of Erdafitinib Compared With
Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial
Cancer and Selected FGFR Gene Aberrations
(Janssen THOR)
| Jan 2018
|
GU- Prostate
| | A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
(Merck 7339-010)
| 2019
|
| | A Phase II randomized trial for intermediate and high risk prostate cancer
Androgen Suppression with Stereotactic Body or External Beam Radiation Therapy (ASSERT)
| 2019
|
| | A Randomised, Double-blind, Placebo-controlled,
Multicentre Phase III Study of Olaparib Plus abiraterone Relative to Placebo
Plus Abiraterone as First-line Therapy in Men with Metastatic
Castration-resistant Prostate Cancer
(Astra Zeneca Propel)
| 2019
|
| | A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD)
(BMS CA209-9KD)
| Nov 2018 |
| | HDR Partial Prostate Brachytherapy as Salvage Treatment for Local Failures After Previous External Beam Radiotherapy
(HDR Salvage-radiation)
| 2018 |
| | A Phase III Randomized Study of Low Dose Rate compared to High Dose Rate Prostate Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
(Monotherapy)
| |
| | Improving quality of life (QOL) after optimal radiotherapy for intermediate and high risk prostate cancer: HDR vs. LDR brachytherapy boost
(QOL-radiation)
| December
2013
|
| GU - Multi | | |
|
Gyne
| | A PHASE II STUDY OF DURVALUMAB AND TREMELIMUMAB IN PATIENTS WITH ADVANCED RARE TUMOURS
(CCTG IND 228 - Rare tumours-Gyne arm only)
| 2019
|
Gyne-Ovary
| | ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
(Clovis Athena)
| 2019 |
Gyne-Cervix
| | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First Line treatment of Persistent, Recurrent, or Metastatic Cervical Cancer. (Merck KEYNOTE 826) | 14May2019
|
Lung
| | |
|
| | A PHASE II/III RANDOMIZED STUDY OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMA
(CCTG IND227) | 16Feb2017
|
| Lymphoma | |
|
|
| Multiple Myeloma | | | |
Melanoma | | A Phase 3 Randomized,
Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib
(E7080/MK-7902) Versus Pembrolizumab Alone as First-line
Intervention in Participants With Advanced Melanoma
(Merck MK-7902-003 / LEAP-003)
| 29Jul2019
|
| Multi-site (endometrial, squamous cell, ovarian, breast, non-small cell lung) | | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
(Tesaro Garnet)
| 8Nov2017
|
| | Phase II non-randomized Trial of Stereotactic Ablative Radiotherapy (SABR) for Oligometastases
(SABR-radiation)
| 1Jan2017
|
Supportive / Palliative Care
| |
|
|
